MDR-reversal activity of chalcones

In Vivo

Volumn 22, Issue 3, 2008, Pages 379-384

  Ivanova, Antoaneta ^a   Batovska, Daniela ^a   Engi, Helga ^b   Parushev, Stoyan ^a   Ocsovszki, Imre ^b   Kostova, Ivanka ^a   Molnar, Joseph ^b  

^a BULGARIAN ACADEMY OF SCIENCES   (Bulgaria)

^b UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Chalcones; Efflux pump; MDR reversal; Multidrug resistance; P glycoprotein

Indexed keywords

3',4',5' TRIMETHOXY 3,4 METHYLENEDIOXYCHALCONE; 3',4',5' TRIMETHOXY 4 ACETAMIDOCHALCONE; 3',4',5' TRIMETHOXY 4 CHLOROCHALCONE; 3',4',5' TRIMETHOXY 4 CYANOCHALCONE; 3',4',5' TRIMETHOXY 4 DIMETHYLAMINOCHALCONE; 3',4',5' TRIMETHOXY 4 METHYLCHALCONE; 3',4',5' TRIMETHOXYCHALCONE; 3',4,4',5' TETRAMETHOXYCHALCONE; 3,3',4,4',5' PENTAMETHOXYCHALCONE; 3,3',4,4',5,5' HEXAMETHOXYCHALCONE; CHALCONE; CHALCONE DERIVATIVE; EPIRUBICIN; MULTIDRUG RESISTANCE PROTEIN 1; RHODAMINE 123; VERAPAMIL;

ANIMAL CELL; ARTICLE; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG STRUCTURE; HUMAN; LYMPHOMA CELL; MOUSE; MULTIDRUG RESISTANCE; NITROBLUE TETRAZOLIUM TEST; NONHUMAN; STRUCTURE ACTIVITY RELATION;

EID: 45949103189     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Endicott JA and Ling V: The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 58: 137-171, 1989.
2. Higgins CF: ABC transporters: from microorganisms to man. Annu Rev Cell Biol 8: 67-113, 1992.
3. Gottesman MM and Pastan I: Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62: 385-427, 1993.
4. Ford JM and Hait WN: Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 42: 155-199, 1990.
5. Chauffert B, Martin M, Hammann A, Michel M-F and Martin F: Amiodarone-induced enhancement of doxorubicin and 4′-deoxydoxorubicin cytotoxicity to rat cancer cells in vitro and in vivo. Cancer Res 46: 825-830, 1986.
6. Twentyman PR: Cyclosporins as drug resistance modifiers. Biochern Pharmcol 43: 109-117, 1992.
7. Dhainaut A, Regnier G, Atassi G, Pierre A, Leonce S, Kraus-Berthier L and Prost JF: New triazine derivatives as potent modulators of multidrug resistance. J Med Chem 35: 2481-2496, 1992.
8. Cassady JM: Natural products as a source of potential cancer chemotherapeutic agents. J Nat Prod 53: 23-41, 1990.
9. Makita H, Tanaka T, Fujitsuka H, Tatematsu N, Satoh K, Hara A and Mori H: Chemoprevention of 4-nitroquinoline-1-oxide-induced rat oral carcinogenesis by the dietary flavonoids chalcone, 2 hydroxychalcone and quercetin. Cancer Res 56: 4904-4909, 1996.
10. Hsieh HK, Lee TH, Wang JP, Wang JJ and Lin CN: Synthesis and anti-inflammatory effect of chalcones and related compounds. Pharm Res 15: 39-46, 1998.
11. Torigoo T, Arisawa M, Iloch S, Fujiu M and Mayuyama HB: Antimutagenic chalcones: antagonizing the mutagenicity of benzo(a)pyrene in Salmonella typhymurium. Biochem Biophys Res Commun 112: 833-842, 1983.
12. Haraguchi H, Ishikawa H, Mizutani K, Tamura Y and Kinoshira T: Antioxidative and superoxide scavenging activities of retrochalcones in Glycyrrhiza inflata. Bioorg Med Chem 6: 339-347, 1998.
13. Ruby AJ, Kuttan G, Sathyanarayana K and Rao MNA: Tumor reducing and antioxidant activities of synthone-substituted chalcones. J Clin Biochem Nutrition 17: 73-80, 1994.
14. De Vincenzo R, Ferlini C, Distefano M, Gaggini C, Riva A, Bombardelli E, Morazzini P, Valenti P, Belluti F, Ranelletti FO, Mancuso S and Scambia G: In vitro evaluation of newly developed chalcone analogues in human cancer cells. Cancer Chem Pharmacol 46: 305-312, 2000.
15. Bois F, Boumendjel A, Mariotte AM, Conseil G and Di Petro A: Synthesis and biological activity of 4-alkoxy chalcones: potential hydrophobic modulator of P-glycoprotein-mediated multidrug resistance. Bioorg Med Chem 7: 2691-2695, 1999.
16. Bhat BA, Dhar KL, Puri SC, Saxena AK, Shanmugavel M and Qazi GN: Synthesis and biological evaluation of chalcones and their derived pyrazoles as potential cytotoxic agents. Bioorg Med Chem Let 15(12): 3177-3180, 2005.
17. Batovska D, Parushev S, Slavova A, Tsvetkova I, Ninova M and Najdenski H: Study on the substituent effects of a series of synthetic chalcones against the yeast Candida albicans. Eur J Med Chem 42: 87-92, 2007.
18. Ferreira MJU, Duarte N, Gyemant N, Radics R, Cherepnev G, Varga A and Molnar J: Interaction between doxorubicin and the resistance modifier stilbene on multidrug resistant mouse lymphoma and human breast cancer cells. Anticancer Res 26: 3541-3546, 2006.
19. Cornwell MM, Pastan I and Gottesmann MM: Certain calcium channel blockers bind specifically to multidrug-resistant human KB carcinoma membrane vesicles and inhibit drug binding to P-glycoprotein. J Biol Chem 262: 2166-2170, 1987.
20. Saponara S, Kawase M, Shah A, Motohashi N, Molnar J, Ugocsai K, Sparagli G and Fusi F: 3,5-Dibenzoyl-4-(3-phenoxyphenyl)-1,4-dihydro-2,6-dimethylpyridine (DP7) as a new multidrug resistance reverting agent devoid of effects on vascular smooth muscle contractility. Br J Pharmacol 141(3): 415-422, 2004.
21. Molnar J, Gyemant N, Mucsi I, Molnar A, Szabo M, Kortvelyesi T, Varga A, Molnar P and Toth G: Modulation of multidrug resistance and apoptosis of cancer cells by selected carotenoids. In Vivo 18(2): 237-244, 2004.
22. Lawrence NJ, Rennison D, McGown AT, Ducki S, Gul LA, Hadfield JA and Khan N: Linked parallel synthesis and MTT bioassay screening of substituted chalcones. J Comb Chem 3: 421-426, 2001.